Volume 13, Issue 4 (2023)                   JMBS 2023, 13(4): 0-0 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Rahbarizadeh F. Toxicity and immunization; two fundamental challenges of developing immunotoxins. JMBS 2023; 13 (4)
URL: http://biot.modares.ac.ir/article-22-60630-en.html
Department of Medical Biotechnology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran , rahbarif@modares.ac.ir
Abstract:   (533 Views)
Immunotoxins are an attractive way to treat cancer; in this method, high-cytotoxic protein toxins target cancer cells specifically. An immunotoxin consists of a targeting component (an antibody, cytokine, or other protein that binds to the cell), that is chemically conjugated or fused in DNA level to a cytotoxic cargo (a bacterium, plant or cytotoxic human protein). Immunotoxin, with the help of specific receptors, recognizes the target cell and enters the cell by endocytosis. After entering the cytocell, it kills the target cancer cell with the help of a toxic component. Although various immunotoxins with different structures have been studied and tested in recent decades, only three immunotoxins Denileukin Diftitox, Tagraxofusp and Moxestumomab Pasudotox - have been clinically approved for the treatment of leukemia. In this article, we review important research and two challenges in production and development of immunotoxins that have limited their clinical success. Further, we highlight methods to overcome these obstacles. These challenges include target and non-target cell toxicity and immunization.
Full-Text [PDF 827 kb]   (229 Downloads)    
Article Type: Systematic Review | Subject: Molecular biotechnology
Received: 2022/04/6 | Accepted: 2022/08/27 | Published: 2023/11/19

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.